Gastroschisis Clinical Pathway

The UC Gastroschisis Clinical Pathway was created after completing a retrospective analysis of inborn gastroschisis patients at all five UC medical campuses. The pathway has been updated based on ongoing monitoring and evaluation. The pathway provides suggested guidelines, which are endorsed by the University of California Fetal Care Consortium with the goal of standardizing and improving care by reducing the percentage of Cesarean deliveries, ventilator days, antibiotic days, opioid doses, parenteral nutrition days, silo days, exposure to general anesthesia, length of stay, and cost.

Obstetrical Guidelines

- Routine preterm delivery is not recommended. In otherwise routine pregnancies with fetal gastroschisis and no other maternal or fetal indications for earlier delivery, delivery at 38 weeks is recommended to minimize the risk of perinatal mortality. In pregnancies with fetal gastroschisis that are complicated by fetal growth restriction or suboptimal interval fetal growth, the goal gestational age for delivery is 37 weeks (although earlier delivery may become indicated).
- Vaginal delivery is recommended with Cesarean section reserved for obstetrical indications.

Surgical Guidelines

- Attempt at bedside silo-placement and closure without intubation or anesthesia is encouraged when feasible (note: a narrow fascial defect requiring lateral extension does not prohibit this approach).
- For bedside silo-placement / closure, recommend placing peripheral IV, pulse oximeter, nasal cannula (in case supplemental oxygen is required), and an orogastric tube (which should be suctioned manually during reduction of bowel).
- If silo is utilized, closure within 3 days is recommended when feasible.
- Recommend gastric and rectal decompression as strategies to facilitate reduction.

Ventilator Guidelines

- Routine intubation and paralysis are not recommended for silo placement or bedside reduction.

Antibiotic Guidelines

- Ampicillin and gentamicin are recommended as primary choice for prophylaxis.
- Discontinue antibiotics ≤ 48 hours after abdominal closure in the absence of culture-positive sepsis or clinical instability.

Pain Management Guidelines

- Recommend oral sucrose water for bedside silo-placement, reduction, and closure.
• Recommend use of non-opioid medications to control pain.
• If opioids are administered during bedside silo placement or skin closure, limit to a single dose when feasible to help prevent apnea and intubation.
• If opioids are utilized, discontinue ≤ 48 hours after abdominal closure.

Central Venous Access Guidelines

• Peripherally-inserted (PICC) venous access is preferred over central-insertion of tunneled central venous catheters.
• Discontinue central venous catheters as soon as 100kcal/kg/day of enteral feeds (or ad lib oral feeds) are achieved.

Nutrition Guidelines

• Encourage oral care protocol with colostrum/maternal breastmilk at least 4x daily beginning first day of life.
• Recommend parenteral nutrition (Dextrose + amino acids) should be the first IV fluids provided. Recommend starting IV lipids prior to 6 hours of life.
  • Protein 2-2.5 g/kg/d
  • Lipids 1-2 g/kg/d
  • GIR 5-8
• Recommend reaching goal parenteral protein and lipid and calories by day of life 3 (as tolerated).
  • Goal protein:
    • 3-3.5 g/kg for term
    • 3.5-4 g/kg for late pre-term or earlier
  • Goal lipid:
    • 3g/kg
  • Goal calories
    • 90-110 kcal/kg/day
• Recommend oral feeds.
• Recommend use of breast milk or consider donor breastmilk as a transition if maternal breastmilk not available. Donor breast milk to be preferred as a transition if maternal milk not available. Once at 60-100 cc/kg/d of donor milk, recommend transitioning to formula.
• Recommend advancing feeds by ≥ 20 cc/kg/d as tolerated.
• Recommend not checking gastric residuals unless clinically indicated.
• Recommend minimizing pauses in feeding unless patient is demonstrating bilious/bloody emesis, abnormal abdominal exam, grossly bloody stools, changes in vital signs or other signs of obstruction or ischemic bowel.
• Growth parameters (weight, length, HC z-scores) should be measured and assessed weekly. Changes in growth parameter z-scores should be assessed.
  • Birth measurements should be used to determine change in z-score
  • If patient is demonstrating a decrease in weight or length z-score from birth that is greater than or equal to -0.8 after 14 days of life, patient’s caloric goal should be increased (i.e. consider fortification and/or increase volume of feeds)

DISCLAIMER: All information provided is for educational and informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. The UCfC does not recommend or endorse any specific treatments, tests, results, physicians, centers, products, procedures, opinions, or other information that may be included in this summary. Further, there are no representations or warranties regarding errors, omissions, completeness or accuracy of the information provided.
Medical Legal Disclaimer:
Welcome to the UC Davis Health, Department of Pediatrics, Clinical Practice Guidelines Website. All health and health-related information contained within the Site is intended chiefly for use as a resource by the Department’s clinical staff and trainees in the course and scope of their approved functions/activities (although it may be accessible by others via the internet). This Site is not intended to be used as a substitute for the exercise of independent professional judgment. These clinical pathways are intended to be a guide for practitioners and may need to be adapted for each specific patient based on the practitioner’s professional judgment, consideration of any unique circumstances, the needs of each patient and their family, and/or the availability of various resources at the health care institution where the patient is located. Efforts are made to ensure that the material within this Site is accurate and timely but is provided without warranty for quality or accuracy. The Regents of the University of California; University of California, Davis; University of California, Davis, Health nor any other contributing author is responsible for any errors or omissions in any information provided or the results obtained from the use of such information. Some pages within this Site, for the convenience of users, are linked to or may refer to websites not managed by UC Davis Health. UC Davis Health does not control or take responsibility for the content of these websites, and the views and opinions of the documents in this Site do not imply endorsement or credibility of the service, information or product offered through the linked sites by UC Davis Health. UC Davis Health provides limited personal permission to use the Site. This Site is limited in that you may not:

- Use, download or print material from this site for commercial use such as selling, creating course packets, or posting information on another website.
- Change or delete propriety notices from material downloaded or printed from it. · Post or transmit any unlawful, threatening, libelous, defamatory, obscene, scandalous, inflammatory, pornographic, or profane material, any propriety information belonging to others or any material that could be deemed as or encourage criminal activity, give rise to civil liability, or otherwise violate the law.
- Use the Site in a manner contrary to any applicable law.

You should assume that everything you see or read on this Site is copyrighted by University of California or others unless otherwise noted. You may download information from this Site as long as it is not used for commercial purposes, and you retain the proprietary notices. You may not use, modify, make multiple copies, or distribute or transmit the contents of this Site for public or commercial purposes without the express consent of UC Davis Health.